Identifying SARS-CoV-2 Lineage Mutation Hallmarks and Correlating Them With Clinical Outcomes in Egypt: A Pilot Study
0301 basic medicine
QH301-705.5
Evolutionary biology
Infectious disease (medical specialty)
Coronavirus Disease 2019 Research
FOS: Health sciences
Biochemistry, Genetics and Molecular Biology (miscellaneous)
Biochemistry
Gene
Coronavirus Disease 2019
03 medical and health sciences
Virology
Health Sciences
Genetics
Pathology
Molecular Biosciences
Disease
Biology (General)
Molecular Biology
Biology
Lineage (genetic)
Pandemic
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Ebola Virus Research and Outbreaks
3. Good health
Coronavirus disease 2019 (COVID-19)
Coronavirus
Infectious Diseases
NGS
FOS: Biological sciences
Mutation
Medicine
Egypt
C36 lineage
mutation
DOI:
10.3389/fmolb.2022.817735
Publication Date:
2022-03-08T10:07:58Z
AUTHORS (12)
ABSTRACT
The SARS-CoV-2 pandemic has led to over 4.9 million deaths as of October 2021. One of the main challenges of creating vaccines, treatment, or diagnostic tools for the virus is its mutations and emerging variants. A couple of variants were declared as more virulent and infectious than others. Some approaches were used as nomenclature for SARS-CoV-2 variants and lineages. One of the most used is the Pangolin nomenclature. In our study, we enrolled 35 confirmed SARS-CoV-2 patients and sequenced the viral RNA in their samples. We also aimed to highlight the hallmark mutations in the most frequent lineage. We identified a seven-mutation signature for the SARS-CoV-2 C36 lineage, detected in 56 countries and an emerging lineage in Egypt. In addition, we identified one mutation which was highly negatively correlated with the lineage. On the other hand, we found no significant correlation between our clinical outcomes and the C36 lineage. In conclusion, the C36 lineage is an emerging SARS-CoV-2 variant that needs more investigation regarding its clinical outcomes compared to other strains. Our study paves the way for easier diagnosis of variants of concern using mutation signatures.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (61)
CITATIONS (1)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....